English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background In general, large-scale clinical trials are needed to make definitive conclusions regarding changes in treatment practice. This is because treatment effects are often modest and large numbers of patients are needed to detect such differences with sufficient power for robust conclusions. Such trials are difficult and often impossible in rare diseases and their worth in this setting could be questioned and this drives the need to consider a different approach.

Trials in rare diseases: the need to think differently